Full bibliography

I found the recent study by Alkhalfan et al. for identifying uric acid as a potential biomarker for lipedema and lymphedema through untargeted plasma metabolomics. To further enhance the clinical translation of these findings, I, propose a structured framework comprising baseline control characterization, longitudinal uric acid profiling across treatment phases, multi-analyte biomarker integration, and endocrine-based stratification. This approach aims to improve diagnostic specificity, accommodate inter-individual variability, and establish uric acid as a reliable tool in differentiating and monitoring lymphatic disorders.